Table 2.

Modeled Prevalence of vtDR Subtypes with Associated Treatment Approach.

Subtype of vtDR	Prevalence among all adults with vtDR (%)	Treatment approach	Source
Severe NPDR without DME	91.0	Close monitoring three times annually	Varma et al 16
No or mild-moderate DR with DME	5.8	DRCR Protocol I, ranibizumab with deferred laser arm	Zhang et al 17
Severe NPDR with DME	0.6	DRCR Protocol I, ranibizumab with deferred laser arm	Gross et al 18
PDR without DME	2.1	DRCR Protocol S, PRP arm	Elman et al 19
PDR with DME	0.6	DRCR Protocol S, ranibizumab arm	Elman et al 19

Note: Figures weighted to reflect the WUSTL primary care patient population.

DME, diabetic macular edema; DR, diabetic retinopathy; DRCR, Diabetic Retinopathy Clinical Research Network; NPDR, nonproliferative DR; PDR, proliferative DR; vtDR, vision-threatening DR.